×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ASND – ascendis pharma a/s - ordinary share (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ASND
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/20
08:00 am
asnd
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
Low
Report
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
4/16
10:15 am
asnd
Ascendis Pharma A/S (ASND) had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (ASND) had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a "buy" rating on the stock.
4/9
09:16 am
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.
Medium
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.
4/8
12:00 pm
asnd
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
Low
Report
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
4/8
08:01 am
asnd
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
Low
Report
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
4/6
04:01 pm
asnd
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
Low
Report
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
4/6
11:33 am
asnd
How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma's (ASND) Pipeline Strategy [Yahoo! Finance]
Low
Report
How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma's (ASND) Pipeline Strategy [Yahoo! Finance]
4/4
08:33 am
asnd
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial [Yahoo! Finance]
Low
Report
Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/11/2026
04:01 pm
ASND
ascendis pharma a/s - ordinary share
MISS
Report
-1.5%
ascendis pharma a/s - ordinary share
11/12/2025
04:01 pm
ASND
ascendis pharma a/s - ordinary share
MISS
Report
3.1%
ascendis pharma a/s - ordinary share
8/7/2025
04:01 pm
ASND
ascendis pharma a/s - ordinary share
BEAT
Report
0.6%
ascendis pharma a/s - ordinary share
5/1/2025
04:01 pm
ASND
ascendis pharma a/s - ordinary share
MISS
Report
2.7%
ascendis pharma a/s - ordinary share
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/21
09:23 am
asnd
Form 6-K Ascendis Pharma A/S For: Apr 21
Medium
Report
Form 6-K Ascendis Pharma A/S For: Apr 21
4/20
09:00 am
asnd
Form 8-A12B/A Ascendis Pharma A/S
Low
Report
Form 8-A12B/A Ascendis Pharma A/S
4/20
08:02 am
asnd
Form 6-K Ascendis Pharma A/S For: Apr 20
Low
Report
Form 6-K Ascendis Pharma A/S For: Apr 20
4/16
06:01 am
asnd
Form 6-K Ascendis Pharma A/S For: Apr 15
Low
Report
Form 6-K Ascendis Pharma A/S For: Apr 15
4/8
04:03 pm
asnd
Form 6-K Ascendis Pharma A/S For: Apr 08
Medium
Report
Form 6-K Ascendis Pharma A/S For: Apr 08
4/8
04:01 pm
asnd
Form 6-K Ascendis Pharma A/S For: Apr 08
Medium
Report
Form 6-K Ascendis Pharma A/S For: Apr 08
4/7
06:03 am
asnd
Form 6-K Ascendis Pharma A/S For: Apr 06
Low
Report
Form 6-K Ascendis Pharma A/S For: Apr 06
4/1
04:10 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 23 Filed by: BIENAIME JEAN JACQUES
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 23 Filed by: BIENAIME JEAN JACQUES
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/20
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Oppenheimer Holdings Inc. from $199.00 to $219.00. They now have an "outperform" rating on the stock.
9.1%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
TOP News Decliners
6/26
Form 6-K Ascendis Pharma A/S For: Jun 26
-9.8%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: